Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Rhea-AI Summary

Compugen (Nasdaq:CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.

The trial evaluates COM701 as maintenance treatment in relapsed platinum-sensitive ovarian cancer, with initial data expected by Q1 2027.

News Market Reaction – CGEN

+1.01%

1 alert

+1.01% Session close to close

$196.67M Market Cap

0.0x Rel. Volume

In the Jun 18 session, CGEN gained 1.01%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reinforces COM701’s MAIA-ovarian program, with initial data expected by Q1 2027. H...

Analysis

This announcement reinforces COM701’s MAIA-ovarian program, with initial data expected by Q1 2027. History shows mixed reactions to event-related news. An effective $400,000,000 shelf and recent insider net selling remain key overhangs to monitor.

Key Figures

ClinicalTrials.gov ID: NCT06888921 Initial data timing: Q1 2027 Poster number: 170 +2 more

5 metrics

ClinicalTrials.gov ID NCT06888921 MAIA-ovarian adaptive platform trial of COM701

Initial data timing Q1 2027 Initial data from MAIA-ovarian adaptive trial expected by Q1 2027

Poster number 170 ESMO Gynaecological Cancers Congress 2026 poster presentation number

Poster date June 18, 2026 Date of COM701 MAIA-ovarian trial-in-progress poster presentation

Presentation time 12:45–13:30 CEST ESMO Gynaecological Cancers Congress 2026 poster session window

Historical Context

5 past events · Latest: Jun 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 11	Clinical poster update	Positive	+4.1%	Announcement of MAIA-ovarian COM701 trial-in-progress poster at ESMO conference.
Jun 08	AI/ML fireside chat	Neutral	-0.2%	Participation in Jones Trading AI/ML-based drug development fireside chat series.
May 18	Q1 2026 earnings	Positive	+4.0%	Q1 2026 results highlighting solid cash balance, no debt and clinical progress.
May 12	Conference participation	Neutral	-1.4%	Announcement of presentation at 2026 Stifel Virtual Targeted Oncology Forum.
May 04	Earnings date notice	Neutral	-2.6%	Scheduling notice for release of first quarter 2026 financial results and call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions, with clinical and earnings updates more often drawing modestly positive moves than conference or scheduling items.

Key Terms

trial-in-progress, adaptive platform trial, platinum-sensitive ovarian cancer, anti-pvrig antibody

4 terms

trial-in-progress clinical

"today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial"

An ongoing clinical study whose enrollment and data collection are currently active but final results have not yet been published; it signals that a company is testing a drug, device, or intervention in people and the outcome is still pending. Investors care because an active trial represents a potential future catalyst — successful results can boost value while setbacks can hurt it — similar to a live construction project that will change a building’s worth once completed.

adaptive platform trial clinical

"MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class"

An adaptive platform trial is a flexible clinical study design that tests multiple treatments at once and adjusts which drugs, doses, or patient groups are pursued as results come in. Think of it like a single kitchen testing several recipes and quickly favoring the ones that work while dropping or changing the others — this can speed development, cut costs, and reduce risk for investors by identifying winners and failures faster than traditional one-at-a-time trials.

platinum-sensitive ovarian cancer medical

"MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard"

A form of ovarian cancer that previously responded to platinum-based chemotherapy and then recurs after a substantial treatment-free interval (commonly six months or more), meaning the tumor is still likely to respond to additional platinum drugs. Think of it like a fire that was put out but flares up again after a pause and can often be controlled with the same extinguisher; for investors, that reliability affects clinical trial design, likelihood of drug approval, market size and pricing for new treatments.

anti-pvrig antibody medical

"COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO"

An anti-PVRIG antibody is a laboratory-made protein designed to stick to and block PVRIG, a molecular “brake” on certain immune cells, so those cells can attack cancer more effectively. For investors, these antibodies matter because they are potential drug candidates: clinical trial results, safety, and regulatory decisions can strongly influence a developer’s prospects and share value, much like a new engine can change a car’s performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark.

"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting exists," said Eran Ophir, Ph.D., President and CEO of Compugen. "COM701 is well tolerated and has previously shown consistent, durable responses in heavily pre-treated patients with platinum-resistant ovarian cancer. As highlighted in our poster, the differentiated biology of the PVRIG pathway, together with its high expression in ovarian cancer and prior clinical signals, supports our evaluation of COM701 in the MAIA-ovarian adaptive trial, with initial data expected by Q1 of 2027."

Poster details:

Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.

Poster presentation number: 170

Date and time of poster presentation: June 18, 2026, 12:45 - 13:30 CEST

Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com

About COM701

COM701 is Compugen's potential first-in-class anti-PVRIG antibody, a novel immune checkpoint identified through Compugen's computational discovery platform. COM701 has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with data demonstrating initial signs of anti-tumor activity and a favorable safety and tolerability profile. COM701 is currently being evaluated in the randomized MAIA-ovarian adaptive platform trial as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from the COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding Compugen's expectation of receiving initial data from the COM701 MAIA-ovarian trial by Q1 2027; statements regarding the clinical and biological rationale for evaluating COM701 as a maintenance therapy in relapsed platinum-sensitive ovarian cancer; and statements regarding the potential of COM701 as a first-in-class anti-PVRIG antibody. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: clinical trials of COM701 or any other product candidate may fail to satisfactorily demonstrate safety and efficacy, and Compugen may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of its product candidates; and general market, political and economic conditions in the countries in which Compugen operates, including Israel and the effect of the ongoing war in Israel. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:

Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

View original content:https://www.prnewswire.com/news-releases/compugen-presents-a-trial-in-progress-poster-on-the-maia-ovarian-adaptive-platform-trial-at-esmo-gynaecological-cancers-congress-302804129.html

SOURCE Compugen Ltd.

FAQ

What did Compugen (CGEN) present at ESMO Gynaecological Cancers Congress 2026?

Compugen presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701 in ovarian cancer. According to Compugen, the trial evaluates COM701 maintenance treatment in relapsed platinum-sensitive ovarian cancer at ESMO Gynaecological Cancers Congress 2026 in Copenhagen.

What is the MAIA-ovarian adaptive platform trial of COM701 for Compugen (CGEN)?

The MAIA-ovarian trial is an adaptive platform clinical study testing COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer. According to Compugen, it evaluates safety and efficacy of COM701 maintenance treatment where no standard-of-care option exists in this setting.

When are initial data from Compugen’s MAIA-ovarian COM701 trial expected?

Initial data from Compugen’s MAIA-ovarian adaptive platform trial of COM701 are expected by Q1 2027. According to Compugen, this trial focuses on maintenance treatment in relapsed platinum-sensitive ovarian cancer and follows earlier signals seen in heavily pre-treated platinum-resistant patients.

What cancer indication is targeted in Compugen’s MAIA-ovarian COM701 trial (CGEN)?

The MAIA-ovarian trial targets relapsed platinum-sensitive ovarian cancer in the maintenance treatment setting. According to Compugen, there is currently no standard-of-care maintenance therapy in this context, and COM701 is being evaluated for safety and efficacy as a potential option.

Who presented Compugen’s MAIA-ovarian COM701 poster and when?

Dr. Oladapo Yeku of Massachusetts General Hospital presented the MAIA-ovarian COM701 poster on June 18, 2026. According to Compugen, the presentation took place from 12:45 to 13:30 CEST at ESMO Gynaecological Cancers Congress 2026 in Copenhagen.

Where can investors access Compugen’s MAIA-ovarian COM701 poster after ESMO 2026?

The MAIA-ovarian COM701 poster will be available on Compugen’s website in the publications section. According to Compugen, investors and clinicians can review the trial-in-progress poster at www.cgen.com following its presentation at ESMO Gynaecological Cancers Congress 2026.